<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726698</url>
  </required_header>
  <id_info>
    <org_study_id>NL53561.042.16</org_study_id>
    <nct_id>NCT02726698</nct_id>
  </id_info>
  <brief_title>Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electrical Remodeling, and Vascular Destabilisation in the Progression of Atrial Fibrillation</brief_title>
  <acronym>RACE V</acronym>
  <official_title>Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electrical Remodeling, and Vascular Destabilisation in the Progression of Atrial Fibrillation - An Observational Exploratory Study on Pathophysiological Mechanisms of AF Progression and on the Role of LinQ/CareLink Guided Patient Tailored Therapy in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to study clinical factors and (blood) biomarkers related to
      progression of Atrial Fibrillation (AF) in patients diagnosed with self-terminating AF with
      special reference to hypercoagulability. All patients will be continuously monitored for
      their atrial rhythm to assess AF progression, either through an implantable loop recorder
      (Reveal LinQ) or via the atrial lead of a cardiac implantable electronic device (CIED), both
      in combination with the CareLink home monitoring system. Remote monitoring and interrogation
      will be installed and used on a daily basis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of AF burden</measure>
    <time_frame>2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac and Cerebrovascular Events</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in therapy due to continuous rhythm monitoring with the LinQ/Carelink system</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with paroxysmal (self-terminating) AF in the cardiology outpatient department,
        first (heart) aid and pacemaker clinic.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New onset or history of paroxysmal, self-terminating AF documented as:

               -  AF on ECG or Holter-recording or loop recorder

               -  Subclinical AF detected in implantable cardiac devices (atrial read &gt; 190 beats
                  per minute, lasting &gt; 6 minutes).

          -  Prior history of self-terminating AF is allowed;

          -  Able and willing to sign informed consent for the registry;

          -  Able and willing to undergo implantation of an implantable loop recorder (in patients
             without a CIED);

          -  In patients already on oral anticoagulation drugs, the following inclusion criteria
             need to be met (to allow for safe temporary interruption of anti-thrombotic treatment
             for coagulation phenotyping):

               -  CHA2DS2-VASc score ≤5 (history of Congestive heart failure, Hypertension, Age ≥
                  75 years (doubled), Diabetes mellitus,Stroke/transient ischemic attack (doubled),
                  Vascular disease, Age 65-75 years, female Sex);

               -  No other indication for oral anticoagulation (e.g. mechanical valve prosthesis);

               -  Patient is willing to temporarily stop oral anticoagulation drugs (OAC).

        Exclusion Criteria:

          -  Non-self-terminating, persistent AF;

          -  Deemed unsuitable or not willing to undergo implantation of loop recorder (in patients
             without a CIED);

          -  Refusing to temporarily stop OAC for coagulation phenotyping (in patients already on
             OAC before inclusion in this study);

          -  On waiting list for pulmonary vein isolation or expected to be placed on waiting list
             within one year;

          -  Expected to start with amiodarone;

          -  Pregnancy;

          -  Life expectancy of less than 2.5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry JGM Crijns, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle C van Gelder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ömer Erküner, MD</last_name>
    <phone>0031433871612</phone>
    <email>omer.erkuner@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruben R de With, MD</last_name>
    <phone>0031503614681</phone>
    <email>r.r.de.with@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin EW Hemels, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ömer Erküner, MD</last_name>
      <phone>0031433871612</phone>
      <email>omer.erkuner@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Harry JGM Crijns, MD, PhD</last_name>
      <phone>0031433871587</phone>
      <email>hjgm.crijns@mumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruben R de With, MD</last_name>
      <phone>0031503614681</phone>
      <email>r.r.de.with@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle C van Gelder, MD, PhD</last_name>
      <phone>0031503611327</phone>
      <email>i.c.van.gelder@umcg.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Martini Hospital</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Tieleman, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ommelander Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert van der Galiën</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombophilia</mesh_term>
    <mesh_term>Atrial Remodeling</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

